Prolacta Bioscience's PreemieFort enteral solution, made entirely from human milk, gets prescription status in Japan for vulnerable infants, a pivotal development in neonatal care.

In a groundbreaking development, Japan has approved Prolacta Bioscience’s human milk fortifiers as prescription medication for fragile infants facing significant health risks.

Japan's Ministry of Health has approved Prolacta Bioscience's human milk-based fortifiers as prescription drugs for vulnerable infants, revolutionizing neonatal care.

Clinigen's approval of PreemieFort® Enteral Solution in Japan marks a significant milestone in neonatal care. This first of its kind human milk-based product enhances nutrition for vulnerable infants.

Prolacta Marks NICU Awareness Month, Celebrating Two Decades Bringing 100% Breastmilk-Based Fortifiers & Formulas to NICUs Nationwide DUARTE, Calif., Sept. 2, 2026 /PRNewswire/ -- Prolacta Bioscience® is marking NICU Awareness Month and 20 years of providing 100% human breastmilk-based...

Prolacta Bioscience marks two decades of innovation in NICU nutrition, providing 100% human milk-based products for babies under 3 pounds.

This is "The Breastmilk Ecology: Genesis of Infant Nutrition (BEGIN) Project" by Prolacta Bioscience on Vimeo, the home for high quality videos and the…

Japan’s Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort® Enteral Solution as Prescription Medicine in the NICU DUARTE, Calif., Feb. 19, 2026 /PRNewswire/ — Prolacta Bioscience® today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved PreemieFort® Enteral Solution, a 100% human milk-based fortifier, as a prescription drug for very low birth weight infants, infants with congenital gastrointestinal disorders or congenital heart diseases, and those recovering from gastrointestinal surgery. This regulatory milestone […]

Clinigen obtained approval for Prolacta’s “PreemieFort® Enteral Solution”, a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the “Nutritional management of neonates and infants presenting with weight gain failure such as very low birth weight (VLBW) infants.” The approval was supported by data from the pivotal Japan-based JASMINE Phase III clinical […]

The JASMINE trial shows that Prolacta's human milk-based fortifiers lead to superior growth in premature infants while preserving Japan's low NEC rates.

Prolacta Bioscience has announced that Japan has officially approved its 100% human milk-based fortifiers, marking a new era in neonatal care for vulnerable infants in the NICU.

Prolacta Bioscience has made history as Japan approves its human milk-based fortifiers as prescription drugs for vulnerable infants. This milestone enhances neonatal care.

Japan has made a groundbreaking decision by approving Prolacta Bioscience's PreemieFort® Enteral Solution as a prescription medication, marking a significant advancement in neonatal care.

Prolacta Bioscience celebrates a key achievement in neonatal care as U.S. NICUs predominantly utilize its breastmilk-based solutions, enhancing outcomes for premature infants.

Prolacta Bioscience is renowned for its innovative 100% human milk-based nutritional solutions for critically ill infants, marking two decades of excellence.

Prolacta Bioscience marks a major milestone during NICU Awareness Month, aiding over 125,000 premature infants with its unique breast milk formulas.

Recent research indicates that premature infants fed Prolacta's Exclusive Human Milk Diet experience significantly lower risks of motor skill disabilities by age 3 compared to those given cow milk-based products.

Prolacta's Surgifort offers a groundbreaking solution for infants recovering from gastroschisis surgery, utilizing FDA-approved donor milk nutrition.